Found 1 Presentation For Request "559P"
559P - Neratinib in HER2-mutant, recurrent/metastatic cervical cancer (R/M CC): Updated findings from the phase 2 SUMMIT basket trial
- Claire F. Friedman (New York, United States of America)
Abstract
Background
Somatic
Methods
Patients (pts) with R/M CC and
Results
As of Mar 18, 2022, 22 pts with CBR, CR + PR + SD ≥16 weeks; CR, complete response; DoR, duration of response; NE, not estimable; ORR, objective response rate; PFS, progression-free survival; PR, partial response; SD, stable disease
Prior bevacizumab Total (N=22) Yes (n=16) No (n=6) 3 (19) 1 (17) 4 (18) CR 1 (6) 0 1 (5) PR 2 (13) 1 (17) 3 (14) 19 (4–46) 17 (0–64) 18 (5–40) 5.9 (5.6–9.3) 12.3 (NE) 7.6 (5.6–12.3) 7 (44) 3 (50) 10 (46) CR 1 (6) 0 1 (5) PR 2 (13) 1 (17) 3 (14) SD (≥16 weeks) 4 (25) 2 (33) 6 (27) 44 (20–70) 50 (12–88) 46 (24–68) 4.4 (1.7–7.2) 5.5 (1.7–20.1) 5.1 (1.7–7.2)
Conclusions
These encouraging results support the clinical benefit of neratinib in this patient population and warrant further investigation following platinum failure.
Clinical trial identification
NCT01953926.
Editorial acknowledgement
Lee Miller, Miller Medical Communications Ltd., provided editorial/writing assistance for this abstract.
Legal entity responsible for the study
Puma Biotechnology, Inc.
Funding
Puma Biotechnology, Inc.
Disclosure
C.F. Friedman: Non-Financial Interests, Personal, Advisory Board: Merck, Genentech; Financial Interests, Personal, Other, Consultant: Seagen, BMS. A.V. Tinker: Financial Interests, Personal and Institutional, Advisory Board: AztraZeneca; Financial Interests, Personal and Institutional, Funding: AztraZeneca; Financial Interests, Personal, Invited Speaker: GSK; Financial Interests, Personal, Advisory Board: GSK, Eisai, Viatris. J.W. Goldman: Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Advisory Board: Genentech, Eli Lilly, Janssen, AbbVie; Financial Interests, Institutional, Invited Speaker: AstraZeneca, Genentech, Eli Lilly, Janssen, BMS, AbbVie. S. Loi: Financial Interests, Institutional, Research Grant: Novartis, Bristol Meyers Squibb, Merck, Puma Biotechnology, Eli Lilly, Nektar Therapeutics, AstraZeneca, Roche-Genentech, Seattle Genetics; Financial Interests, Institutional, Other, Consultant: Aduro Biotech, Novartis, GlaxoSmithKline, Roche-Genentech, AstraZeneca, Silverback Therapeutics, G1 Therapeutics, Puma Biotechnologies, Pfizer, Gilead Therapeutics, Seattle Genetics, Daiichi Sankyo, Merck, Amunix, Tallac Therapeutics, Eli Lilly, Bristol Meyers Squibb. M. Melisko: Financial Interests, Institutional, Research Grant, PI on Clinical Trial: Novartis, KCRN, Puma Biotechnology. A. Oaknin: Financial Interests, Personal, Advisory Board: AstraZeneca, Clovis Oncology, Deciphera Pharmaceuticals, Genmab, GSK, ImmunoGen, Mersana Therapeutics, PharmaMar, Roche, Tesaro, Merck Sharps & Dohme de España, SA, Agenus, Sutro, Corcept Therapeutics, EMD Serono, Novocure, prIME Oncology, Sattucklabs, Itheos, Eisai, F. Hoffmann-La Roche,; Financial Interests, Personal, Other, Travel and accomodation: AstraZeneca, PharmaMar, Roche; Financial Interests, Institutional, Funding: Abbvie Deutschland, Advaxis Inc., Aeterna Zentaris, Amgen, Aprea Therapeutics AB, Clovis Oncology Inc, EISAI limited LTD, F. Hoffmann –La Roche LTD, Regeneron Pharmaceuticals, ImmunoGen Inc, Merck, Sharp & Dohme de España SA, Millennium Pharmaceuticals Inc, PharmaMar SA, Tesaro Inc., Bristol Myers Squibb; Non-Financial Interests, Leadership Role, Executive Board member as a Co-Chair: GEICO; Non-Financial Interests, Leadership Role, Phase II Committee and Cervix Cancer Committee Representative on behalf of GEICO: GCIG; Non-Financial Interests, Officer, Chair of Gynaecological Track ESMO 2019. Scientific Track Member Gynaecological Cancers ESMO 2018, ESMO 2020, ESMO 2022. Member of Gynaecological Cancers Faculty and Subject Editor Gyn ESMO Guidelines.: ESMO; Non-Financial Interests, Member: ESMO, ASCO, GCIG, SEOM, GOG. I. Spanggaard: Financial Interests, Institutional, Principal Investigator: Roche, Puma Biotechnology, MSD, Genentech, Incyte, AstraZeneca, Orion, Pfizer; Financial Interests, Institutional, Research Grant: Genmab, Bristol-Myers Squibb, Loxo/Bayer, Loxo/Lilly, Novartis. A.L. Frazier: Financial Interests, Personal, Full or part-time Employment: Puma Biotechnology, Inc.; Financial Interests, Personal, Stocks/Shares: Puma Biotechnology, Inc. B. Zhang: Financial Interests, Personal, Full or part-time Employment: Puma Biotechnology, Inc.; Financial Interests, Personal, Stocks/Shares: Puma Biotechnology, Inc. L.D. Eli: Financial Interests, Personal, Full or part-time Employment: Puma Biotechnology, Inc.; Financial Interests, Personal, Stocks/Shares: Puma Biotechnology, Inc. D.B. Solit: Financial Interests, Personal, Advisory Board: Pfizer, Loxo/Lilly Oncology, Scorpion Therapeutics, Vividion Therapeutics, FORE Therapeutics, BridgeBio; Financial Interests, Personal, Stocks/Shares: Scorpion Therapeutics, Vividion Therapeutics, FORE Therapeutics. All other authors have declared no conflicts of interest.